MedPath

Midomafetamine

Generic Name
Midomafetamine
Drug Type
Small Molecule
Chemical Formula
C11H15NO2
CAS Number
42542-10-9
Unique Ingredient Identifier
KE1SEN21RM
Background

An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

Indication

Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.

Clinical Trials
Related News

The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.

Phase 1
Withdrawn
Conditions
Post Traumatic Stress Disorder
Interventions
First Posted Date
2018-11-26
Last Posted Date
2024-05-17
Lead Sponsor
Yale University
Registration Number
NCT03752918
Locations
🇺🇸

Connecticut Mental Health Center, New Haven, Connecticut, United States

MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function

Phase 1
Not yet recruiting
Conditions
Pharmacokinetics
Hepatic Impairment
Interventions
First Posted Date
2018-07-31
Last Posted Date
2024-10-30
Lead Sponsor
Lykos Therapeutics
Target Recruit Count
16
Registration Number
NCT03606538
Locations
🇺🇸

Alliance for Multispecialty Research, LLC., Knoxville, Tennessee, United States

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)

Phase 3
Completed
Conditions
Posttraumatic Stress Disorder
Interventions
Behavioral: Therapy
Drug: Placebo
First Posted Date
2018-05-25
Last Posted Date
2025-01-08
Lead Sponsor
Lykos Therapeutics
Target Recruit Count
100
Registration Number
NCT03537014
Locations
🇺🇸

Trauma Research Foundation, Boston, Massachusetts, United States

🇨🇦

Dr. Simon Amar, Inc., Montreal, Quebec, Canada

🇮🇱

Sheba Fund for Health Services and Research, Tel HaShomer, Israel

and more 12 locations

Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction

Early Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2018-05-17
Last Posted Date
2022-01-19
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
30
Registration Number
NCT03527316
Locations
🇨🇭

Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland

Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)

Phase 2
Completed
Conditions
Posttraumatic Stress Disorder
Interventions
Behavioral: Manualized therapy
First Posted Date
2018-04-02
Last Posted Date
2024-11-20
Lead Sponsor
Lykos Therapeutics
Target Recruit Count
4
Registration Number
NCT03485287
Locations
🇨🇦

British Columbia Centre on Substance Abuse, Vancouver, British Columbia, Canada

🇨🇦

Dr. Simon Amar, LLC, Montréal, Quebec, Canada

Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD

Phase 2
Completed
Conditions
PTSD
Interventions
Behavioral: Manualized therapy
First Posted Date
2017-09-13
Last Posted Date
2024-11-20
Lead Sponsor
Lykos Therapeutics
Target Recruit Count
38
Registration Number
NCT03282123
Locations
🇺🇸

Zen Therapeutic Solutions, LLC, Mount Pleasant, South Carolina, United States

🇺🇸

Affective Care, New York, New York, United States

🇺🇸

New School Research LLC, North Hollywood, California, United States

and more 9 locations

Evaluation of MDMA on Startle Response

Phase 1
Completed
Conditions
Startle Response
Interventions
Drug: Placebo
Behavioral: Acoustic startle
First Posted Date
2017-06-09
Last Posted Date
2025-03-04
Lead Sponsor
Lykos Therapeutics
Target Recruit Count
34
Registration Number
NCT03181763
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

Effects of MDMA on Emotional and Social Memories

Not Applicable
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2017-02-13
Last Posted Date
2018-06-29
Lead Sponsor
University of Chicago
Target Recruit Count
84
Registration Number
NCT03050541

Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing

Early Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2017-01-13
Last Posted Date
2018-10-15
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
28
Registration Number
NCT03019822
Locations
🇨🇭

University Hospital Basel, Basel, Basel Stadt, Switzerland

MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD

Phase 1
Completed
Conditions
Posttraumatic Stress Disorder
Interventions
Behavioral: CBCT
Behavioral: Therapy
First Posted Date
2016-08-23
Last Posted Date
2025-05-18
Lead Sponsor
Lykos Therapeutics
Target Recruit Count
12
Registration Number
NCT02876172
Locations
🇺🇸

Offices of Michael Mithoefer MD, Mount Pleasant, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy